Angelman syndrome (AS) is a rare neurogenetic disease with an estimated prevalence of one in 10,000 to 20,000 births. It is characterized by cognitive, developmental and autism-like deficits, including speech impediments, disturbed sleep, seizures, jerky movements, frequent laughter or smiling and, usually, a happy disposition. It is caused by a dysfunctional maternally inheritedUbe3A gene. The gene’s encoded protein, ubiquitin protein ligase, is required to degrade another protein, activity-regulated cytoskeletal-associated protein (Arc), which controls synaptic strength or plasticity. If Arc is not degraded, its accumulation weakens synaptic contacts and impairs cognitive and motor functions.
In a series of experiments using the 129-Ube3atm1Alb/J ("AS," 004477) mouse, a model of Angelman syndrome, a research team led by John Marshall, M.D., from Brown University, Providence, R.I., identified specific synaptic signaling factors affected by excess Arc levels. The team found that normalizing Arc expression in this mouse rescues the signaling deficits and may be a promising therapy for people with Angelman syndrome (Cao et al. 2013).
The AS mouse has abnormally high levels of the Arc protein and has deficits in long-term potentiation (LTP) and learning (Jiang et al. 1998; Bliss and Collingridge 1993). LTP is a long-lasting synapse regulator that is widely thought to facilitate learning and memory (Cooke and Bliss 2006). To appreciate the work of the Marshall team, a basic understanding of several molecules that play key roles in neuronal synapse and LTP is helpful:
The Marshall team found that excess Arc in the AS mouse interferes with BDNF signaling by binding to PSD-95 and other synapse effectors, preventing their association with TrkB, an association without which BDNF signaling cannot fully occur. By disrupting the Arc/PSD-95 interaction with CN2097, a novel synthetic compound that binds PSD-95, the Marshall team normalized BDNF signaling and improved LTP induction in the AS mouse.
In summary, the Marshall team's results indicate that, in their AS mouse model, excess Arc due to Ube3A deficiency interferes with TrkB's ability to interact with key factors necessary for BDNF signaling. A compound that disrupts excess Arc binding to PSD-95 may be therapeutic for people with AS.
We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.